TEVA•benzinga•
Teva and Medincell Announces FDA Acceptance Of Supplemental New Drug Application for UZEDY(R) Extended-Release Injectable Suspension As A Treatment For Patients With Bipolar I Disorder
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga